Hadassah

Hadassah Cardiologist is Key Researcher in Identifying Genetic Heart Mutation

Tuesday, Sep 1 2015

"Some 2.4 percent of the population suffers from mitral valve prolapse, where one of the valves that controls blood flow through the heart doesn't close properly,” reports Dr. Durst.

Dr. Ronen Durst, a senior cardiologist at the Hadassah Medical Organization and a Hebrew University researcher, is a key member of the international team that has identified a genetic mutation linked to mitral valve prolapse.

Dr. Durst is the first author of the article about this genetic mutation published in the prestigious British science journal, Nature.

The international collaborative research team, led by Massachusetts General Hospital (MGH), where Durst was working in the Center for Human Genetic Research and the Division of Cardiology, had been seeking a genetic connection to this common cardiac problem, which often runs in families. The research led to the discovery of the mutation in the DCHS1 gene in affected members of three families.

"Some 2.4 percent of the population suffers from mitral valve prolapse, where one of the valves that controls blood flow through the heart doesn't close properly,” reports Dr. Durst. “This abnormality,” he brings out, “often causes serious problems in heart rhythm, infections, and even sudden death.”

Dr. Robert Levine of MGH’s Corrigan Minehan Heart Center, co-senior author of the Nature paper, notes: “This finding can teach us how to prevent this inborn disease from manifesting as an illness in people who inherit mutated forms of the gene. Understanding how defects in this gene cause errors in early valve formation can point to ways we can prevent the progression of this condition to keep the valve and the heart healthy and help the patient avoid complications.”

Nature's acceptance of this study, Dr. Durst says, “underlines its international importance and strengthens the link between researchers at Hadassah Hospital and the Hebrew University of Jerusalem with colleagues in prestigious laboratories abroad, such as Harvard and the hospitals with which it is affiliated.”

Comments

From: dvasha on September 10, 2015
pls email this article to me and how I can stay aware of significant developments. Tx.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Aug 16 2017

Gazan Boy Walks for First Time at Hadassah

Unable to stand on his feet, suffering from severe respiratory distress, a four-year-old boy from Gaza gained the ability to walk once Hadassah Hospital surgeons identified and removed a large tumor lodged in his chest.

READ MORE ›
alt_text

Wednesday, Aug 16 2017

Hadassah Hosts Health Innovation Conference

Over one hundred doctors, researchers, and entrepreneurs gathered at Hadassah Hospital Ein Kerem this summer to discuss how to advance the quality of patient care with computational power.

READ MORE ›
alt_text

Monday, Aug 14 2017

Hadassah Hosts First Human Trial with Drug to Fight Nasty Bacterial Infection

Immuron, an Australian biopharmaceutical company, has received approval from the Hadassah Medical Organization’s ethics committee and Israel’s Ministry of Health to begin its first clinical trial with a new drug to fight a bacterial infection called Clostridium Difficile (CDI).

READ MORE ›
alt_text

Thursday, Aug 3 2017

Mystery of Devastating Pediatric Disease Solved by Hadassah Team

A genetic mutation causing a rare and devastating pediatric neurological disease that has puzzled medical centers around the world has been identified at the Hadassah Medical Organization by Prof. Orly Elpeleg, head of Hadassah's Department of Genetics and Metabolic Diseases.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More